EUCTR2016-001443-39-CZ进行中（未招募）1 期
A Randomised, Parallel Arm, Placebo-Controlled, Double-Blind, Study of the Safety and Efficacy of PRX167700 Added to Existing Non-steroidal Anti-inflammatory Therapy in Adults with Moderate-to-Severe Knee Pain Due to Osteoarthritis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Participants who have symptomatic primary knee OA for at least 3 months prior to Screening. Participants must have had pain in the target knee for = 14 days per month in the 3 months preceding screening.
- •2. A diagnosis of knee OA based on American College of Rheumatology criteria with X-ray confirmation (a Kellgren-Lawrence X-ray grade of 2 - 3) in the target joint. X-rays taken within the last 12 months may be used for confirmation. One knee should be designated as the target joint. The pain in the target knee joint should exceed the pain experienced in other joints (including the contralateral knee joint and/or ipsilateral hip joint) and pain experienced from any concomitant medical condition.
- •3. Stable oral NSAID therapy for the treatment of knee OA for at least 5 of 7 days each week for the 4 weeks preceding the Screening visit (Visit 1). Stable therapy is considered to be use of the same dose of the same NSAID for the required number of days each week.
- •4. A moderate to severe pain score of = 8 and = 16 in the target knee joint evaluated by the WOMAC Pain Score at the Screening Visit (Visit 1), at the start of the Placebo Run-in (Visit 2), and at Baseline (Visit 3, Day 0).
- •5. The same or worse pain at Baseline (Visit 3, Day 0) compared to their WOMAC Pain Score at the start of the Placebo Run-in (Visit 2).
- •6. Body Mass Index (BMI) between 18 and 40 kg/m2, inclusive.
- •7. Male or female participants between 50 and 75 years of age, inclusive.
- •8. Female participants are eligible to participate in the study if they meet one of the following criteria:
- •a. They are not of child-bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is postmenopausal as defined in Appendix 5)
- •b. They are of child-bearing potential, are not pregnant or lactating, are sexually active, and have a negative pregnancy test at Screening (Visit 1, serum test from central lab), Visit 2 (urine dipstick method in the clinic), and Baseline (Visit 3, urine dipstick method in the clinic). WOCBP who are sexually active must agree to use an highly effective contraception method during the study. A highly effective contraception method is defined as:
- •i. Established use of oral, injected or implanted hormonal methods of contraception.
- •ii. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- •iii. Sole male partner is vasectomised.
- •iv. Bilateral tubal occlusion.
- •c.They are of childbearing potential, are not pregnant or lactating, are sexually abstinent, and have a negative pregnancy test at Screening (Visit 1, serum test from central lab), Visit 2 (urine dipstick method in the clinic), and Baseline (Visit 3, urine dipstick method in the clinic). WOCBP who are sexually abstinent at the start of the study must agree to remain abstinent for the duration of the study.
- •9. Able to provide written informed consent to participate in the study and, in the opinion of the investigator, able to read, comprehend and record information as required by the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1.Causes of secondary arthritis of the knee, including septic arthritis, autoimmune joint disease, crystalline diseases, gout, articular fracture, and inherited disorders.
- •2. Pain relating to the target joint that has characteristics of neuropathic pain (eg, shooting or burning pain, pins and needles, allodynia, or reflex sympathetic dystrophy).
- •3. Disease of the spine or of lower extremity joints (other than OA) which contribute to the pain in the target joint.
- •4. Lower extremity surgery (including arthroscopy) within 6 months prior to Screening (V1) or scheduled for surgery of any kind during the study.
- •5. Significant injury to the target joint within 12 months prior to Screening (V1).
- •7. Active autoimmune disease or conditions requiring chronic immunosuppressive therapy, including rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, and organ transplant recipient.
- •8. Known history of hypersensitivity or intolerance to paracetamol or NSAIDs.
- •9. Known or current history of clinically relevant gastrointestinal bleeding or symptoms within the last 3 months consistent with silent or symptomatic gastrointestinal ulceration
- •10. Clinically significant illness other than OA within 3 months prior to Screening (V1) which might interfere with the conduct of the trial.
- •11. History of malignancy within past 5 years (except for basal cell carcinoma or carcinoma-in-situ of the cervix treated with curative intent).
- •13. Poorly controlled hypertension at Screening (V1) defined as systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg measured after 5 minutes rest in the supine position. A repeat measure is allowed for the increased blood pressure if judged by the investigator to be white coat syndrome. Initiation of antihypertensive medication(s) is permitted prior to study entry. Blood
- •pressure must be re-assessed on 2 occasions separated by at least one hour. Mean SBP/DBP values must be < or = 160/100 for eligibility at screening.
- •15. Substantial renal dysfunction, defined as creatinine clearance calculated using Cockroft Gault equation < 60 mL/min.
- •20. Participants with any active medical condition or previous major abdominal surgery or procedure that might, in the investigator's opinion, have a significant effect on drug absorption, distribution, metabolism, or excretion.
- •22. Use of analgesics other than NSAIDs for the treatment of knee OA for at least 25 days out of 30 days preceding the Screening visit (V1). This includes, paracetamol, tramadol, opioid-containing preparations,
- •gabapentin, and pregabalin (other preparations may be considered on a case-by-case basis)
- •23. For 14 days prior to first dose of study treatment(s) treatment, taking any agent with high risk to prolong the QTc interval or to cause Torsades de Pointes (TdP)
- •24. Corticosteroid injections before Screening (V1):
- •- Intra-articular into the target joint within 3 months
- •-Intra-articular into any site other than the target joint within 1 month
- •-Intra-muscular within 3 months
- •25. Other therapeutic injections into the target joint within previous 3 months.
- •26. Systemic corticosteroids within 1 month of Screening (V1).
- •27. Use of any anti-inflammatory biological therapy within 12 months prior to Screening (V1).
- •30. Previous exposure to PRX167700.
- •31. Receipt of an investigational product within 30 days or 5 half-lives or twice the duration of the biological effect of the investigational product, whichever i
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the safety and effect of a drug called PRX167700 on a painful chronic condition, osteoarthritis in the kneesOsteoarthritis of the kneeMedDRA version: 20.0Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2016-001443-39-PLBenevolentAI Cambridge Ltd.190
进行中（未招募）
1 期
A clinical trial to investigate the safety and effect of a drug called PRX167700 on a painful chronic condition, osteoarthritis in the kneesOsteoarthritis of the kneeMedDRA version: 20.0 Level: LLT Classification code 10023476 Term: Knee osteoarthritis System Organ Class: 100000004859EUCTR2016-001443-39-GBProximagen Ltd.202
进行中（未招募）
1 期
A clinical trial to investigate the safety and effect of a drug called PRX167700 on a painful chronic condition, osteoarthritis in the kneesEUCTR2016-001443-39-HUProximagen Ltd.170
进行中（未招募）
1 期
A a study to assess the safety and efficacy of PRX167700 compared to placebo in patients with Moderate to Severe Knee Pain Due to Osteoarthritis who cannot be treated with oral non steroidal anti inflammatory therapy.Moderate to Severe Knee Pain Due to Osteoarthritis in subjects who are Inappropriate for Oral Non steroidal Anti inflammatory TherapyMedDRA version: 20.0Level: PTClassification code 10031161Term: OsteoarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: LLTClassification code 10031165Term: Osteoarthritis kneeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: LLTClassification code 10024776Term: Localised osteoarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: LLTClassification code 10031166Term: Osteoarthritis kneesSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-001185-20-GBProximagen Limited141
已完成
2 期
Clinical study of Anti Hangover Drink NE-AB01 in reducing alcohol induced hangover symptoms in adult male social drinkers.CTRI/2019/05/019412aturedge Beverages Pvt Ltd60